Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 583

1.

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.

Clay-Gilmour AI, Kumar S, Rajkumar SV, Rishi A, Kyle RA, Katzmann JA, Murray DL, Norman AD, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM.

Leukemia. 2018 Sep 10. doi: 10.1038/s41375-018-0246-2. [Epub ahead of print]

PMID:
30201985
2.

Optimising collaborator recruitment and maintaining engagement via social media during large multi-centre studies: lessons learned from the National Audit of Small Bowel Obstruction (NASBO).

Sayers AE, Lee MJ, Smart N, Fearnhead NS; NASBO steering group.

Colorectal Dis. 2018 Sep 1. doi: 10.1111/codi.14394. [Epub ahead of print]

PMID:
30171749
3.

Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.

Rombach I, Gray AM, Jenkinson C, Murray DW, Rivero-Arias O.

BMC Med Res Methodol. 2018 Aug 28;18(1):87. doi: 10.1186/s12874-018-0542-6.

4.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Rajkumar SV, Kyle RA, Kumar S, Kapoor P.

Am J Hematol. 2018 Aug 19. doi: 10.1002/ajh.25254. [Epub ahead of print]

PMID:
30121949
5.

Partial factorial trials: comparing methods for statistical analysis and economic evaluation.

Dakin HA, Gray AM, MacLennan GS, Morris RW, Murray DW.

Trials. 2018 Aug 16;19(1):442. doi: 10.1186/s13063-018-2818-x.

6.

MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms.

Kourelis T, Murray DL, Dasari S, Kumar S, Barnidge D, Madden B, Arendt B, Milani P, Merlini G, Ramirez-Alvarado M, Kyle RA, Dispenzieri A.

Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25244. [Epub ahead of print] No abstract available.

PMID:
30105838
7.

Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS.

Exp Hematol. 2018 Aug 10. pii: S0301-472X(18)30749-5. doi: 10.1016/j.exphem.2018.08.002. [Epub ahead of print]

PMID:
30102945
8.

Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization.

Mirzayans R, Andrais B, Murray D.

Cancers (Basel). 2018 Aug 1;10(8). pii: E255. doi: 10.3390/cancers10080255.

9.

Factors affecting intraosseous pressure measurement.

Beverly M, Murray D.

J Orthop Surg Res. 2018 Jul 28;13(1):187. doi: 10.1186/s13018-018-0877-z.

10.

Defenses against Pro-oxidant Forces - Maintenance of Cellular and Genomic Integrity and Longevity.

Murray D, Mirzayans R, McBride WH.

Radiat Res. 2018 Jul 24. doi: 10.1667/RR15101.1. [Epub ahead of print]

PMID:
30040046
11.

Age and Outcomes of Medial Meniscal-Bearing Unicompartmental Knee Arthroplasty.

Kennedy JA, Matharu GS, Hamilton TW, Mellon SJ, Murray DW.

J Arthroplasty. 2018 Oct;33(10):3153-3159. doi: 10.1016/j.arth.2018.06.014. Epub 2018 Jun 20.

PMID:
30006108
12.

Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.

Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, Cornthwaite K, Karapetis CS, Pedersen SK.

J Cancer Res Clin Oncol. 2018 Jul 10. doi: 10.1007/s00432-018-2701-x. [Epub ahead of print]

PMID:
29992492
13.

Decision-making skills improve with critical care training: Using simulation to measure progress.

Murray DJ, Boyle WA, Beyatte MB, Knittel JG, Kerby PW, Woodhouse J, Boulet JR.

J Crit Care. 2018 Oct;47:133-138. doi: 10.1016/j.jcrc.2018.06.021. Epub 2018 Jun 25.

PMID:
29981998
14.

Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0194-x. [Epub ahead of print] No abstract available.

PMID:
29977017
16.

Comparison of statistical approaches for analyzing incomplete longitudinal patient-reported outcome data in randomized controlled trials.

Rombach I, Jenkinson C, Gray AM, Murray DW, Rivero-Arias O.

Patient Relat Outcome Meas. 2018 Jun 21;9:197-209. doi: 10.2147/PROM.S147790. eCollection 2018.

17.

The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study.

Burn E, Edwards CJ, Murray DW, Silman A, Cooper C, Arden NK, Prieto-Alhambra D, Pinedo-Villanueva R.

Clin Epidemiol. 2018 Jun 14;10:697-704. doi: 10.2147/CLEP.S160347. eCollection 2018.

18.

The impact of eculizumab on routine complement assays.

Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL.

J Immunol Methods. 2018 Sep;460:63-71. doi: 10.1016/j.jim.2018.06.010. Epub 2018 Jun 20.

PMID:
29935209
19.

A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL.

Blood. 2018 Aug 9;132(6):670-672. doi: 10.1182/blood-2018-05-848986. Epub 2018 Jun 11. No abstract available.

PMID:
29891533
20.

Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.

Symonds EL, Pedersen SK, Murray DH, Jedi M, Byrne SE, Rabbitt P, Baker RT, Bastin D, Young GP.

Clin Epigenetics. 2018 May 16;10:63. doi: 10.1186/s13148-018-0500-5. eCollection 2018.

Supplemental Content

Loading ...
Support Center